Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be highlighted in several presentations by leading physicians at the upcoming Society of Robotic Surgery (“SRS”) Annual Meeting to be held in Fort Lauderdale, FL, July 23-26, 2026.

MAIN CONGRESS SESSIONS

Real-world Outcomes after MRI-guided Transurethral Ultrasound Ablation of the Prostate in a Multicenter Post-market Registry Xiaosong Meng, MD, PhD; UT Southwestern Medical Center, Dallas, TX July 24, 2026; 9:55:10:00 a.m. EDT

CAPTAIN Randomized Controlled Trial of MRI-guided Transurethral Ultrasound Ablation (TULSA) vs. Radical Prostatectomy: Primary Safety Outcomes Xiaosong Meng, MD, PhD; UT Southwestern Medical Center, Dallas, TX July 24, 2026; 10:00-10:04 a.m. EDT

MRI-Guided Transurethral Ultrasound Ablation (TULSA) for Localized Prostate Cancer: Single-Center Efficacy and Safety Outcomes Xiaosong Meng, MD, PhD; UT Southwestern Medical Center, Dallas, TX July 24, 2026; 10:30-10:34 a.m. EDT

Intermediate Term Oncologic and Functional Outcomes of Incisionless Robotic Prostatectomy (Whole-Gland TULSA) for Extreme Apical Prostate Cancer Victoria Y. Bird, MD; National Medical Association and Research Group, Gainesville, FL July 24, 2026; 10:46-10:50 a.m. EDT

Salvage MRI-Guided Transurethral Ultrasound Ablation (TULSA) for Locally Recurrent Prostate Cancer Following Focal Therapy or Radiation: Oncologic and Functional Outcomes from a Single-Center Cohort Victoria Y. Bird, MD; National Medical Association and Research Group, Gainesville, FL July 24, 2026; 10:50-10:55 a.m. EDT

B...